

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Guy A. Rouleau *et al.*

Serial No.: 10/664,423

Filed: September 17, 2003

For: LOCI FOR IDOPATHIC GENERALIZED
EPILEPSY, MUTATIONS THEREOF
AND METHOD USING SAME TO
ASSESS, DIAGNOSE, PROGNOSIS OR
TREAT EPILEPSY

Group Art Unit: 1649

Examiner: Daniel E. Kolker

Atty. Dkt. No.: GOUD:023USD2

CERTIFICATE OF ELECTRONIC SUBMISSION

DATE OF SUBMISSION: October 16, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. § 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(e) no item of information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Supplemental Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Supplemental Information Statement. Therefore, No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. § 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:023USD2.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Michael R. Krawzsenek
Reg. No. 51,898
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: October 16, 2006

Form PTO-1449 (modified)		Atty. Docket No. G0UD:023USD2	Serial No. 10/664,423
List of Patents and Publications for Applicant's		Applicant Guy A. Ronleau <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: September 17, 2003	Group: 1649
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C75	"Table of Contents," <i>Annals of the New York Academy of Sciences</i> , 868, 1999.
	C76	Clare <i>et al.</i> , "Cloning and Functional Analysis of the Type III Na ⁺ Channel from Human Brain," <i>Annals of the New York Academy of Sciences</i> , 868:80-83, 1999.
	C77	GenBank Accession No. AF035685 and AF035686.
	C78	Rudinger, "Characteristics of the amino acids as components of a peptide hormone sequence," In: <i>Peptide Hormones</i> (ed. J.A. Parsons) University Park Press, Baltimore, pp. 1-7, 1976.

25703841 1

EXAMINER:

DATE CONSIDERED:

EXAMINER, INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)